Fox Run Management, L.L.C. Fibrogen Inc Transaction History

Fox Run Management, L.L.C.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	BUY	$0.79 - $2.83 $33,748 - $120,897	42,720 New	42,720 $36,000
Q1 2022 May 10, 2022	SELL	$12.02 - $16.79 $196,935 - $275,087	-16,384 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$9.93 - $15.39 $162,693 - $252,149	16,384 New	16,384 $231,000
Q1 2020 May 08, 2020	SELL	$23.3 - $45.96 $111,583 - $220,102	-4,789 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $165,603 - $230,159	4,789 New	4,789 $205,000
Q4 2018 Jan 15, 2019	SELL	$37.97 - $60.16 $303,760 - $481,280	-8,000 Closed	0 $0
Q3 2018 Oct 05, 2018	BUY	$56.3 - $67.25 $450,400 - $538,000	8,000 New	8,000 $486,000
Q2 2018 Jul 17, 2018	SELL	$44.9 - $64.95 $299,662 - $433,476	-6,674 Closed	0 $0
Q1 2018 Apr 17, 2018	BUY	$45.35 - $61.65 $302,665 - $411,452	6,674 New	6,674 $308,000
Q4 2017 Jan 18, 2018	SELL	$41.95 - $60.1 $734,125 - $1.05 Million	-17,500 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$33.4 - $53.9 $584,500 - $943,250	17,500	17,500 $942,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.